

Book Reviews

Scientists Must Speak. By D. Eric Walters and Gale Climenson Walters. Routledge, London and New York. 2002. xii + 132 pp. 14 × 21.5 cm. ISBN 0-415-28028-1. \$18.95 (paperback).

This book is well written and provides many helpful techniques for the preparation of improved presentations, regardless of the level of the speaker's prior experience. High school and college students preparing to give their first speech, as well as graduate and postgraduate students preparing a seminar or a presentation at a scientific meeting, would be well served having read the many helpful ideas presented. The first three chapters may seem to be rather mundane, but persistence in reading them will provide a useful background for what will be much more relevant chapters (4–11) for college, graduate, and postdoctoral students as well as for mature, experienced teachers. These last chapters are intended to develop an ever-increasing improvement in presentations. Continuous reference to this book by students as they progress through their academic experience has promise for improving oral presentations throughout a scientific career. Experienced faculty members will be well served in their teaching role as a result of having read this book, enabling them to guide their students in preparing and delivering better presentations. This reviewer recommends that *Scientists Must Speak* be utilized by high school students enrolled in a speech class and college students who are required to make oral presentations, as well as graduate and postgraduate students. Faculty members at all levels would also be well served by using this book as a teaching tool. Students who apply the helpful techniques outlined in the book will experience the pride of having presented well.

John R. J. Sorenson

*Division of Medicinal Chemistry
Department of Pharmaceutical Sciences
University of Arkansas, Medical Sciences Campus
Little Rock, Arkansas 72205-7122*

JM020552N

10.1021/jm020552n

New Drugs 2001. Including All Drugs Approved in 2000 and 2001. Edited by G. W. A. Milne. Ashgate

Publishing Company, Burlington, VT. 2002. xxiii + 154 pp. 12.5 × 25 cm. ISBN 0-566-08516-X. \$90.00.

This book covers the 50 major “new molecular entities” (NMEs) approved by the United States Food and Drug Administration (FDA) since January 1, 2000. Also included for reference are a few older drugs and some that have not yet received FDA approval. *New Drugs 2001* is the first of a series that is planned for annual publication.

Following an introductory section that considers the social and scientific factors influencing the development, approval, and marketing of selected classes of new drug products, 179 drug entries are presented according to their therapeutic classification, arranged in alphabetical order ranging from ACE inhibitors to vasodilators. Each entry contains an entry number, the most commonly used name of the drug [usually the U.S. Adopted Name (USAN)], the Chemical Abstracts Service (CAS) registry number, the 13th edition Merck Index number, the European Inventory of Existing Chemical Structures (EINECS) number, chemical structure, chemical name, molecular formula, synonyms and trade names, patent, regulatory and therapeutic use information, physical and toxicity properties, and manufacturer. The book concludes with indexes to the CAS registry number, EINECS number, subjects and synonyms, and a manufacturer directory that provides the names, addresses, and telephone numbers of major pharmaceutical companies.

All concerned with the development of new drug products may find library access to this book and forthcoming annual issues of interest. Clearly, however, there is significant overlap of the subject matter presented in *New Drugs 2001* with that of the Merck Index and with that of *Annual Reports in Medicinal Chemistry*, particularly the “To Market, To Market” chapter, which is regularly included in this series.

Carl Kaiser

*8470 Woodland Road
Millersville, Maryland 21108-1756*

JM0204744

10.1021/jm0204744